Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.55 |
| ▸ | HTR3A | P46098 | 2/20 | 0.55 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.54 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | WNT1 | P04628 | 1/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indisetron SCHEMBL18311525 | 1.00 | NPC1 (0.61) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL1073375 | 1.00 | NPC1 (0.61) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL29398028 | 1.00 | NPC1 (0.61) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL2229963 | 0.99 | NPC1 (0.60) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL15313306 | 0.99 | NPC1 (0.60) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL2948918 | 0.99 | NPC1 (0.60) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL1649312 | 0.98 | NPC1 (0.59) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| SCHEMBL2086084 | 0.91 | NPC1 (0.67) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| SCHEMBL7336988 | 0.90 | NPC1 (0.58) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| SCHEMBL7336990 | 0.90 | NPC1 (0.58) | NPC1RAB9AUSP30DYRK1AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-07-10 | — | — | US | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| WO-2025016899-A1 | SPIROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-23 | — | — | WO | claimed |
| EP-4476221-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-12-18 | — | — | EP | claimed |
| WO-2024188937-A1 | COMBINATIONS OF ATR KINASE INHIBITORS AND PARP INHIBITORS TO TREAT HYPER-PROLIFERATIVE CONDITIONS E.G. CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-19 | — | — | WO | claimed |
| US-20240247015-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-25 | — | — | US | claimed |
| EP-4364742-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | Eisai R&D Management Co., Ltd. (JP) | 2024-05-08 | — | — | EP | claimed |
| US-6429209-B2 | 5-HT3 RECEPTOR ANTAGONISTS SUCH AS ALOSETRON TO TREAT NONCONSTIPATED FEMALE IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM CORPORATION | 2002-08-06 | — | — | US | claimed |
| WO-2002041918-A2 | USE OF A TRIPLE COMBINATION COMPRISING A 5HT3 ANTAGONIST, A 5HT4 AGONIST AND A LAXATIVE FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-30 | — | — | WO | claimed |
| US-20020040033-A1 | Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-04-04 | — | — | US | claimed |
| WO-2002007713-A2 | MEDICAMENTS CONTAINING CILANSETRON FOR TREATING NON-OBSTIPATED MALE IBS PATIENTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-01-31 | — | — | WO | claimed |
| US-20010044450-A1 | Medicaments | SEBELA INTERNATIONAL LIMITED (BM) | 2001-11-22 | — | — | US | claimed |
| US-6284770-B1 | ADMINISTERING SEROTONINE RECEPTOR ANTAGONIST | GLAXO WELLCOME INC. | 2001-09-04 | — | — | US | claimed |
| CN-1281357-A | Medicaments | GLAXO GROUP LTD (GB) | 2001-01-24 | — | — | CN | claimed |
| EP-1021174-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2000-07-26 | — | — | EP | claimed |
| WO-1999017755-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1999-04-15 | — | — | WO | claimed |
| EP-0469449-B1 | Diazabicyclononyl derivatives as 5-HT3 receptor antagonists | NISSHIN FLOUR MILLING CO (JP) | 1997-10-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | NPC1 3060/4885RAB9A 103/4885USP30 2092/4885 |
| US-20010044450-A1 | Medicaments | HTR3A, HTR3E, HTR5A | NPC1 1610/4885RAB9A 4692/4885USP30 396/4885 |
| US-20240247015-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | SOST, PPM1D, SOS1 | NPC1 2068/4885RAB9A 1066/4885USP30 3077/4885 |
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | HTR3C, HTR3D, HTR3A | NPC1 1301/4885RAB9A 779/4885USP30 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.